EBR Systems is super confident the US medical gatekeeper will approve Wise, the world's first wireless pacemaker device.

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

CHARLESTOWN, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB) (the “Company”), a life sciences company developing ...

Due to uncertainty within the data, the impact of looser driving restrictions still merits close scrutiny, a researcher says.

Akura Medical, Inc., a privately held portfolio company of Shifamed LLC that is developing treatments for venous thromboembolis ...

Black and Hispanic patients have increased mortality rates and lower rates of coronary interventions following in-hospital cardiac arrest.

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

One of the seminars will feature NFL Hall of Famer Marshall Faulk, who will discuss the importance of mental health ...

Akura Medical, a Shifamed portfolio company focused on reshaping the landscape of venous thromboembolism (VTE) care, announced today the first patient enrollment in the QUADRA-PE study (NCT06672510) ...

BARBIE HSU - Actress Barbie Hsu's hidden health struggles have been unveiled, revealing the challenges she faced in her battle with epilepsy and heart disease.